HOME >> BIOLOGY >> NEWS
New antimalarial combination confirms its potential use in treating drug-resistant malaria

three-day treatment period; and a second study will compare CDA to Lapdap alone. If the development of CDA is successful, it is expected to be available in 2008 as a convenient, once-daily dose. CDA will be made available to the public sector of malaria-endemic countries at preferential prices in order to maximise its availability to those in need.

CDA is being developed in collaboration with GlaxoSmithKline (GSK), the World Health Organization's Special Programme for Research and Training in Tropical Diseases (WHO/TDR), Medicines for Malaria Venture (MMV), the University of Liverpool, Liverpool School of Tropical Medicine and the London School of Hygiene & Tropical Medicine.

Dr. Robert Ridley, Director of WHO/TDR, stated, "The collaboration between WHO/TDR, MMV, GSK and our academic partners has enabled us to combine resources and expertise to speed the development of CDA."

"GSK is committed to research and development into treatments for diseases of the developing world," said Dr. Lynn Marks, Senior Vice President, Infectious Diseases Medicine Development Centre for GSK. "Public-private partnerships, such as this one for CDA, are vital in ensuring that urgently needed medicines are made available as quickly and safely as possible."


'"/>


15-Nov-2005


Page: 1 2

Related biology news :

1. Cost-effectiveness study of three antimalarial drug combinations in Tanzania
2. Research milestone brings goal closer of cheap antimalarial drug for developing world
3. $43 million from Gates Foundation to produce inexpensive antimalarial drug for Third World
4. Cetuximab and irinotecan combination increases survival in metastatic colorectal cancer
5. New study suggests promising drug combinations for sleeping sickness
6. Recombination protein dynamics observed with single monomer resolution
7. AVELOX as effective as multi-dose combination therapy for intra-abdominal infections
8. New combination treatment induces regression of prostate cancer
9. Avelox as effective as Levofloxacin combination therapy for severe community-acquired pneumonia
10. New observational study suggests use of combination vaccines may improve immunization coverage rates in infants
11. Pesticide combinations imperil frogs, probably contribute to amphibian decline

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/25/2017)... YORK , Jan. 25, 2017 The ... Access Management (IAM) lifecycle is comprised of a ... for the purpose of maintaining digital identities and ... resources and applications. There are significant number of ... from time to time by optimizing processes and ...
(Date:1/21/2017)... Jan 20, 2017 Research and Markets has ... 2017-2021" report to their offering. ... The global voice recognition biometrics market to ... The report covers the present scenario and the growth ... calculate the market size, the report considers the revenue generated from ...
(Date:1/18/2017)... 2017 MedNet Solutions , an ... entire spectrum of clinical research, is proud to ... for the organization in terms of corporate growth, ... products and services. The company,s exceptional achievements can ... iMedNet ™ – ...
Breaking Biology News(10 mins):
(Date:2/20/2017)... 2017  This Report analyzes the worldwide markets for Bioinformatics in ... provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , ... http://www.reportlinker.com/p04707099-summary/view-report.html ... Annual estimates and forecasts are provided for the period 2015 ...
(Date:2/20/2017)... Philadelphia, PA (PRWEB) , ... ... ... technologies to improve therapeutic success among radiotherapy patients, prevent chest wall collapses ... for femur fracture alignments will receive a total of $600,000 in funding ...
(Date:2/19/2017)... ... February 19, 2017 , ... Expanding Portfolio to Include Lab ... equipment with the goal of expanding the reach of its quality and precision ... water analysis meters were introduced into the market in 2014. , The OHAUS ...
(Date:2/17/2017)... February 17, 2017 According ... by Product (Consumables, Service), Type (Safety, Efficacy, Validation), ... Drug Discovery and Development, Disease-Risk) - Global Forecast ... projected to reach USD 53.34 Billion by 2021 ... a CAGR of 13.8% during the forecast period ...
Breaking Biology Technology:
Cached News: